USD 27.65
(2.18%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 947.87 Million USD | -3.21% |
2022 | 979.28 Million USD | 100.2% |
2021 | 489.14 Million USD | 6.85% |
2020 | 457.81 Million USD | 109.17% |
2019 | 218.87 Million USD | 9.62% |
2018 | 199.66 Million USD | 534.08% |
2017 | 31.48 Million USD | 16.15% |
2016 | 27.1 Million USD | 114.37% |
2015 | 12.64 Million USD | -27.03% |
2014 | 17.33 Million USD | 402.06% |
2013 | 3.45 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 836.8 Million USD | -6.2% |
2024 Q1 | 892.08 Million USD | -5.89% |
2023 Q4 | 947.87 Million USD | -5.09% |
2023 Q1 | 1.03 Billion USD | 5.64% |
2023 Q2 | 1.01 Billion USD | -2.07% |
2023 Q3 | 998.7 Million USD | -1.42% |
2023 FY | 947.87 Million USD | -3.21% |
2022 Q2 | 1.04 Billion USD | -0.2% |
2022 Q1 | 1.05 Billion USD | 114.67% |
2022 FY | 979.28 Million USD | 100.2% |
2022 Q4 | 979.28 Million USD | -2.44% |
2022 Q3 | 1 Billion USD | -4.22% |
2021 Q2 | 460.66 Million USD | -3.23% |
2021 Q1 | 476.03 Million USD | 3.98% |
2021 FY | 489.14 Million USD | 6.85% |
2021 Q4 | 489.14 Million USD | -0.32% |
2021 Q3 | 490.7 Million USD | 6.52% |
2020 Q1 | 493.73 Million USD | 125.58% |
2020 Q2 | 491.1 Million USD | -0.53% |
2020 Q3 | 471.15 Million USD | -4.06% |
2020 Q4 | 457.81 Million USD | -2.83% |
2020 FY | 457.81 Million USD | 109.17% |
2019 Q2 | 215.75 Million USD | 3.72% |
2019 FY | 218.87 Million USD | 9.62% |
2019 Q4 | 218.87 Million USD | -0.39% |
2019 Q3 | 219.72 Million USD | 1.84% |
2019 Q1 | 208.01 Million USD | 4.18% |
2018 Q3 | 575.72 Million USD | -2.53% |
2018 Q4 | 199.66 Million USD | -65.32% |
2018 Q2 | 590.64 Million USD | -2.45% |
2018 FY | 199.66 Million USD | 534.08% |
2018 Q1 | 605.45 Million USD | 1822.81% |
2017 Q1 | 25.48 Million USD | -6.01% |
2017 Q3 | 26.4 Million USD | -8.96% |
2017 Q4 | 31.48 Million USD | 19.25% |
2017 Q2 | 29 Million USD | 13.82% |
2017 FY | 31.48 Million USD | 16.15% |
2016 Q4 | 27.1 Million USD | 11.1% |
2016 Q3 | 24.4 Million USD | 15.82% |
2016 Q2 | 21.06 Million USD | 44.23% |
2016 Q1 | 14.6 Million USD | 15.51% |
2016 FY | 27.1 Million USD | 114.37% |
2015 Q2 | 11.75 Million USD | -9.2% |
2015 Q4 | 12.64 Million USD | -6.25% |
2015 FY | 12.64 Million USD | -27.03% |
2015 Q3 | 13.48 Million USD | 14.75% |
2015 Q1 | 12.94 Million USD | -25.3% |
2014 FY | 17.33 Million USD | 402.06% |
2014 Q4 | 17.33 Million USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 FY | 3.45 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Esperion Therapeutics, Inc. | 660.79 Million USD | -43.446% |
Theratechnologies Inc. | 98.63 Million USD | -860.956% |
Safety Shot Inc | 3.89 Million USD | -24254.221% |
Cosmos Health Inc. | 30.25 Million USD | -3033.216% |
Cronos Group Inc. | 43.73 Million USD | -2067.265% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -15.967% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1856.604% |
Organogenesis Holdings Inc. | 181.36 Million USD | -422.644% |
Universe Pharmaceuticals INC | 13.75 Million USD | -6791.48% |
ProPhase Labs, Inc. | 42.54 Million USD | -2127.992% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -10725.457% |
Dynavax Technologies Corporation | 375.02 Million USD | -152.751% |
Radius Health, Inc. | 804.29 Million USD | -17.853% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -10206.808% |
Alvotech | 1.88 Billion USD | 49.65% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -15338.742% |
Alpha Teknova, Inc. | 38.55 Million USD | -2358.761% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | -592.533% |
SCYNEXIS, Inc. | 55.45 Million USD | -1609.427% |
Harrow Health, Inc. | 241.75 Million USD | -292.085% |
Biofrontera Inc. | 23.13 Million USD | -3996.448% |
DURECT Corporation | 30.4 Million USD | -3017.401% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -94.452% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | -100.961% |
OptiNose, Inc. | 194.33 Million USD | -387.754% |
RedHill Biopharma Ltd. | 20.97 Million USD | -4418.407% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | -478.309% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1704.923% |
SIGA Technologies, Inc. | 57.97 Million USD | -1534.911% |
Lifecore Biomedical, Inc. | 219.8 Million USD | -331.245% |
Shineco, Inc. | 47.6 Million USD | -1891.268% |
Phibro Animal Health Corporation | 725.54 Million USD | -30.644% |
Procaps Group S.A. | 462.06 Million USD | -105.139% |
TherapeuticsMD, Inc. | 14.02 Million USD | -6659.927% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -431711.017% |
Viatris Inc. | 27.21 Billion USD | 96.517% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -15338.742% |
Rockwell Medical, Inc. | 30.88 Million USD | -2969.351% |
Incannex Healthcare Limited | 5.83 Million USD | -16158.611% |
Aytu BioPharma, Inc. | 90.37 Million USD | -948.78% |
Tilray Brands, Inc. | 892.11 Million USD | -6.25% |
PetIQ, Inc. | 645.22 Million USD | -46.906% |
Silver Spike Investment Corp. | 3 Million USD | -31392.698% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 7.016% |
Journey Medical Corporation | 56.49 Million USD | -1577.688% |
Alimera Sciences, Inc. | 107.35 Million USD | -782.945% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -4346.834% |
Assertio Holdings, Inc. | 148.41 Million USD | -538.662% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -49894.436% |
Embecta Corp. | 2.03 Billion USD | 53.446% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -11063.931% |
Procaps Group, S.A. | 462.06 Million USD | -105.139% |
PainReform Ltd. | 2.69 Million USD | -35123.969% |
Avadel Pharmaceuticals plc | 173.38 Million USD | -446.683% |
Hempacco Co., Inc. | 18.82 Million USD | -4935.897% |
Talphera, Inc. | 6.29 Million USD | -14969.587% |
Pacira BioSciences, Inc. | 704.25 Million USD | -34.593% |
Alvotech | 1.88 Billion USD | 49.65% |
Lantheus Holdings, Inc. | 835.25 Million USD | -13.483% |
Kamada Ltd. | 109.96 Million USD | -761.955% |
Indivior PLC | 1.95 Billion USD | 51.422% |
Currenc Group, Inc. | 177.67 Million USD | -433.487% |
Evoke Pharma, Inc. | 9.64 Million USD | -9724.511% |
Flora Growth Corp. | 17.22 Million USD | -5403.873% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -11063.931% |
Evolus, Inc. | 209.68 Million USD | -352.044% |
HUTCHMED (China) Limited | 536.38 Million USD | -76.715% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | -8.516% |
Akanda Corp. | 12.66 Million USD | -7381.929% |